Loading, please wait...
Due to concerns about the novel coronavirus, and consistent with ongoing efforts to reduce spread of the virus, attendance for the November CE sessions will be WEBINAR ONLY. Please see instructions below for registration.
PLEASE FOLLOW THE STEP-BY-STEP INSTRUCTIONS BELOW – DO NOT SKIP STEPS!
STEP 1: REGISTER FOR THE CE CREDIT ON THIS SITE
** If you do not register for the CE at this link, you will not be able to access the evaluations to earn credit
** EVERYONE must register BEFORE the session date. NO NEW REGISTRATIONS WILL BE ADDED AFTER THE PROGRAM DATE
** you will receive an email confirming your registration at the email address provided – if you do not receive a confirmation email, try to register again
STEP 2: AFTER SUCCESSFULLY REGISTERING - AT THE TIME OF THE PROGRAM, EXPAND THE MODULE AND CLICK THE WEBEX LINK
** submit your contact information
STEP 3: Collect the presenter code for each of the CEs that you attend
** EVERYONE will need the presenter codes to access evaluations and earn CE credit
STEP 4: You will receive an automated email to log in and complete evaluations
** Evaluations must be completed within 60 days of the CE session
** You will need the presenter codes to access each evaluation
** Evaluations MUST be completed within 60 days of the program date to earn CE credit!
Date: Nov 1, 2020 08:00 PM - Nov 30, 2020 05:00 PM
CE Hours
4.00
CE Units
0.400
Registration closes on Nov 30, 2020 01:00 AM
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Accreditation(s)
Participants have 60 days from the start of their program to claim CE credit and verify it has been upload to CPE Monitor. If your program requires the completion of a post test/eval/survey those items MUST be done before that 60 day window closes to receive credit for that program. Statements of credit can be viewed and printed from CPE Monitor. Statements of credit will no longer be printed and mailed to the participant. **No partial individual session credit will be given**
REGISTRATION NOTE: During the registration process, if a fee is required, please enter the zip code associated with your credit card's BILLING ADDRESS. For security purposes payments are processed through a separate system, so when prompted, please click “ok” to be taken to that site and complete your registration. Upon successful registration of this program you will receive an email confirmation/receipt and will be returned to this program page. When you are retuned to this page you will see a note at the top of the page reading “You are registered for this program.”
If you are not automatically returned to this page or see only a blank white screen your transaction was not successful, and you will need to try again.
If paying by check please mail to the address below: 301 Pharmacy Lane, CB# 7574 Beard Hall
Chapel Hill, NC 27599
|
|
|
The University of North Carolina Eshelman School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To receive CE credit, participants must complete the CE attendance form and the online evaluation of the program (instructions to be emailed). Statements of credit can be viewed and printed in CPE Monitor approximately 2 to 3 weeks after the program and you have completed any needed requirements. **No partial credit will be available**
|
Co-Sponsor(s)
UNC Health System
Support/Credits
Cancelations: Cancelations must be received in writing/email to the Office of Continuing Education at least 48 hours prior to start date to receive a full refund. No refunds will be given within 48 hours of the start date.
IMPORTANT: UNC HEALTH SYSTEM EMPLOYEES AND UNC ESHELMAN SCHOOL OF PHARMACY STUDENTS ONLY
- UNC Health System Employees and UNC ESOP Students should register using your UNC email address. UNC Employees - please select your employment location during the registration process. UNC Students - please respond "Yes" to the "Are you a UNC Student" question.
- Select the “Check” payment method on the registration page to complete your enrollment. Your status will be verified prior to credit being uploaded.
Objectives
- Define basic concepts of ECMO including: development, indications, and cannulation sites
- Review existing society guidelines for anticoagulation in ECMO therapy
- Discuss hematologic effects and resultant complications of ECMO therapy
- Discuss recent data supporting common anticoagulation strategies and modalities for anticoagulation monitoring
- Outline an algorithm to optimize the use of anticoagulation in ECMO therapy
Speaker(s)/Author(s)
|
Sydney Graboyes, PharmD
|
Activity Number
0046-9999-20-351-L01-P
Date:
11/05/20
Time:
05:00 PM - 06:00 PM
CE Hours
1.00
Fee
$10.00
Location
Online
Program held from 1p-2p, then repeated from 2p-3p
Session 1: 1300-1400
Password: Hsm2ANAXR65
Session 2: 1400-1500
Password: B6Ky3uxySS2
Objectives
- Discuss Pharmacokinetics of oral anticoagulation in hemodialysis
- Summarize currently published literature on anticoagulation in hemodialysis
- Discuss ongoing trials analysis oral anticogaulation in dialysis
- Discuss the differences in oral anticoagulation dosing for atrial fibrillation versus venous thromboembolism treatment and prophylaxis in hemodialysis patients.
- Apply literature to a patient case
Speaker(s)/Author(s)
|
Rebecca Farley, PharmD
|
Activity Number
0046-9999-20-343-L01-P
Date:
11/11/20
Time:
01:00 PM - 03:00 PM
CE Hours
1.00
Fee
$10.00
Location
Online
This presentation will provide an educational overview of the key newly published data on the use of remdesivir for the treatment of COVID-19. I will also provide an overview of the pharmacology of remdesivir. This will allow pharmacists to better understand the use appropriate use and potential side effects of this new drug.
Meeting:160 226 3681
Password: UNCPharm1
Objectives
- Briefly describe the pathophysiology of the SARS-CoV-2 virus and COVID-19 disease
- Review the mechanism of action, spectrum of activity, dosing regimens and the adverse effects of the novel antiviral remdesivir
- Summarize key published data on remdesivir for the treatment of COVID-19
Speaker(s)/Author(s)
|
Ashlyn M. Norris, PharmD
|
Activity Number
0046-9999-20-345-L01-P
Date:
11/12/20
Time:
05:00 PM - 06:00 PM
CE Hours
1.00
Fee
$10.00
Location
Online
Heparin has long been the gold standard for anticoagulation in pediatric patients on ECMO. However, it can be associated with heparin-induced thrombocytopenia (HIT) and heparin resistance. This presentation aims to present literature surrounding the use of direct-thrombin inhibitors in pediatric patients on ECMO and compare them to the gold standard.
Meeting: 160 762 1034
Password: UNCPharm1
Objectives
- Identify common pediatric indications for extracorporeal membrane oxygenation (ECMO) and associated complications
- Distinguish the mechanism of action of unfractionated heparin from the direct-thrombin inhibitors
- Analyze advantages and disadvantages of the anticoagulation therapeutic options in pediatric patients on ECMO
- Discuss literature pertaining to the use of alternative anticoagulation in pediatric patients on ECMO
Speaker(s)/Author(s)
|
Amanie Khairullah, PharmD
|
Activity Number
0046-9999-20-359-L01-P
Date:
11/19/20
Time:
05:00 PM - 06:00 PM
CE Hours
1.00
Fee
$10.00
Location
Online